Disease Landscape and Forecast Insights

Multiple well-established therapies are available to treat Crohn’s disease (CD). In particular, the most widely used biologics—the TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/…

Neuropathic pain (NP) is a heterogeneous disorder arising from a wide variety of diseases and conditions, and as a result, patient response to drug therapy is often unpredictable. Treatment of NP…

Market Outlook Chemotherapies and targeted agents continue to dominate the treatment of colorectal cancer, although targeted agents (e.g., Avastin, Erbitux, Vectibix) are currently confined to…

The axial spondyloarthritis (AxSpA) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (AS), has expanded beyond those with spinal…

The primary goals of treatment of Sjögren’s syndrome (SS) are to relieve the hallmark sicca symptoms and minimize the impact and progression of systemic disease manifestations. Although an array…

The axial spondyloarthritis (AxSpA) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (AS), has expanded beyond those with spinal…

Diabetic nephropathy (DN), also known as diabetic kidney disease, refers to kidney function damage caused by diabetes. DN is a leading cause of chronic kidney disease (CKD) and is associated with…

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…

Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-α inhibitors such as Janssen / Merck’s Remicade and AbbVie / Eisai’s Humira helped…

The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in…

The treatment of renal cell carcinoma has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has…

Since the approval of the first biosimilar in Europe more than a decade ago, the use of biosimilars has been increasing in that region. Likewise, the FDA approved the first biosimilar in 2015, and…